Momin Behnoosh R, Pinheiro Paulo S, Carreira Helena, Li Chunyu, Weir Hannah K
Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia.
Epidemiology and Biostatistics, University of Nevada at Las Vegas, Las Vegas, Nevada.
Cancer. 2017 Dec 15;123 Suppl 24(Suppl 24):5059-5078. doi: 10.1002/cncr.30820.
Worldwide, liver cancer is a leading cause of death for both men and women. The number of Americans who are diagnosed with and die of liver cancer has been rising slowly each year. Using data from the CONCORD-2 study, this study examined population-based survival by state, race, and stage at diagnosis.
Data from 37 statewide registries, which covered 81% of the US population, for patients diagnosed during 2001-2009 were analyzed. Survival up to 5 years was adjusted for background mortality (net survival) with state- and race-specific life tables, and it was age-standardized with the International Cancer Survival Standard weights.
Liver cancer was diagnosed overall more often at the localized stage, with blacks being more often diagnosed at distant and regional stages than whites. 5-year net survival was 12.2% in 2001-2003 and 14.8% in 2004-2009. Whites had higher survival than blacks in both calendar periods (11.7% vs 9.1% and 14.3% vs 11.4%, respectively). During 2004-2009, 5-year survival was 25.7% for localized-stage disease, 9.5% for regional-stage disease, and 3.5% for distant-stage disease.
Some progress has occurred in survival for patients with liver cancer, but 5-year survival remains low, even for those diagnosed at the localized stage. Efforts directed at controlling well-established risk factors such as hepatitis B may have the greatest impact on reducing the burden of liver cancer in the United States. Cancer 2017;123:5059-78. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
在全球范围内，肝癌是男性和女性的主要死因。每年被诊断出患有肝癌并死于该病的美国人数量一直在缓慢上升。本研究利用CONCORD-2研究的数据，按州、种族和诊断时的分期对基于人群的生存率进行了分析。
分析了来自37个州登记处的数据，这些登记处覆盖了81%的美国人口，涉及2001年至2009年期间诊断的患者。利用特定州和种族的生命表对长达5年的生存率进行背景死亡率调整（净生存率），并使用国际癌症生存标准权重进行年龄标准化。
总体而言，肝癌在局部阶段被诊断出的情况更为常见，黑人在远处和区域阶段被诊断出的情况比白人更为常见。2001 - 2003年的5年净生存率为12.2%，2004 - 2009年为14.8%。在两个时间段内，白人的生存率均高于黑人（分别为11.7%对9.1%和14.3%对11.4%）。在2004 - 2009年期间，局部阶段疾病的5年生存率为25.7%，区域阶段疾病为9.5%，远处阶段疾病为3.5%。
肝癌患者的生存率已取得一些进展，但5年生存率仍然很低，即使是那些在局部阶段被诊断出的患者。针对控制诸如乙肝等已确定的危险因素的努力，可能对减轻美国肝癌负担产生最大影响。《癌症》2017年；123:5059 - 78。2017年发表。本文是美国政府作品，在美国属于公共领域。
